MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial of efficacy and safety
Keywords: Active-controlled; MP29-02; Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ); allergic rhinitis; azelastine hydrochloride; clinical trial; double-blind; fluticasone propionate; placebo-controlled; randomized; rhinitis treatment; total nasal symptom score (TNSS); total ocular symptom score (TOSS)
Document Type: Research Article
Affiliations: Allergy and Asthma Medical Group and Research Center, San Diego, California, USA
Publication date: 2012-07-01
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
- Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Ingenta Connect is not responsible for the content or availability of external websites